Prostate Cell News Volume 3.27 | Jul 20 2012

May 12, 2022

Prostate Cell News 3.27 July 20, 2012

In this issue: Publications | Industry News | Policy News | Events | Jobs

TOP STORY

Laminin Receptor Specific Therapeutic Gold Nanoparticles (¹⁹⁸AuNP-EGCg) Show Efficacy in Treating Prostate Cancer
Researchers report the development of inherently therapeutic gold nanoparticles derived from the Au-198 isotope; the range of the ¹⁹⁸Au ß-particle is sufficiently long to provide cross-fire effects of a radiation dose delivered to cells within the prostate gland and short enough to minimize the radiation dose to critical tissues near the periphery of the capsule. [Proc Natl Acad Sci USA] Abstract | Press Release | Video

PUBLICATIONS (Ranked by impact factor of the journal)

LABORATORY RESEARCH

Collaboration of Kras and Androgen Receptor Signaling Stimulates EZH2 Expression and Tumor Propagating Cells in Prostate Cancer
Scientists investigated the functional synergy in prostate cancers in mice resulting from activation of the androgen receptor, Kras and Akt, which drive three of the most frequently activated oncogenic signaling pathways in prostate cancer. [Cancer Res] Abstact

CFTR Suppresses Tumor Progression through MicroRNA-193B Targeting Urokinase Plasminogen Activator (uPA) in Prostate Cancer
Researchers demonstrated a previously undefined tumor-suppressing role of cystic fibrosis transmembrane conductance regulator (CFTR) and its involvement in regulation of microRNA-193b in prostate cancer development. [Oncogene] Abstract

PKD2 and PKD3 Promote Prostate Cancer Cell Invasion via uPA by Shifting Balance between NF-κB and Histone Deacetylase 1
Investigators showed that protein kinase D2 (PKD2) and PKD3 promote nuclear factor-kappaB (NF-κB) signaling and urokinase-type plasminogen activator (uPA) expression/activation, which are critical to prostate cancer cell invasion. [J Cell Sci] Abstract

ATRA Inhibits the Proliferation of DU145 Prostate Cancer Cells through Reducing the Methylation Level of HOXB13 Gene
Researchers aimed to elucidate the mechanisms that are involved in the proliferation inhibition of androgen receptor-negative prostate cancer cells triggered by all-trans retinoic acid (ATRA). [PLoS One] Full Article

Rac1 Activation Driven by 14-3-3ζ Dimerization Promotes Prostate Cancer Cell-Matrix Interactions, Motility and Transendothelial Migration
Scientists investigated the role of protein 14-3-3ζ in prostate cancer cell motility and transendothelial migration using biochemical, molecular biology and electric cell-substrate impedance sensing approaches, as well as cell based functional assays. [PLoS One] Full Article

3,3’-Diindolylmethane, but Not Indol-3-Carbinol, Inhibits Histone Deacetylase Activity in Prostate Cancer Cells
Investigators examined the effects of indole-3-carbinol and 3,3’-diindolylmethane on histone deacetylases in human prostate cancer cell lines: androgen insensitive PC-3 cells and androgen sensitive LNCaP cells. [Toxicol Appl Pharmacol] Abstract

Epigenetic Deregulation of miR-29a and miR-1256 by Isoflavone Contributes to the Inhibition of Prostate Cancer Cell Growth and Invasion
Researchers found that the DNA sequence of the promoters of microRNA-29a (miR-29a) and miR-1256 are partly methylated in prostate cancer (PCa) cells, which leads to their lower expression both in PCa cells and in human tumor tissues compared with normal epithelial cells and normal human prostate tissues. [Epigenetics] Abstract

The Prostate Cancer Blocking Potential of the Histone Deacetylase Inhibitor LBH589 Is Not Enhanced by the Multi Receptor Tyrosine Kinase Inhibitor TKI258
The growth-blocking potential of the histone deacetylase-inhibitor LBH589 and the multiple tyrosine kinase-inhibitor TKI258, applied alone or in combination, were investigated in a panel of prostate cancer cell lines. [Invest New Drugs] Abstract

CLINICAL RESEARCH

Phase I Study Investigating the Safety and Feasibility of Combining Imatinib Mesylate (Gleevec) with Sorafenib in Patients with Refractory Castration-Resistant Prostate Cancer
Investigators determined the maximum tolerated dose and the dose-limiting toxicity of sorafenib plus imatinib in castration-resistant prostate cancer patients. [Br J Cancer] Abstract

Phase III, Randomized, Placebo-Controlled Study of Zibotentan in Patients with Castration-Resistant Prostate Cancer Metastatic to Bone
Researchers aimed to determine whether the specific endothelin A receptor antagonist, zibotentan, prolonged overall survival in patients with castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain. [Cancer] Abstract

INDUSTRY NEWS

Accuray to Acquire Morphormics, Inc.
Accuray Incorporated announced they have signed a definitive agreement to acquire Morphormics Inc., a privately held company founded by University of North Carolina at Chapel Hill faculty members based on their research in autosegmentation of medical images. [Accuray Incorporated] Press Release

Cancer Research UK Receives Largest Ever Donation
Cancer Research UK has been given a gift of £10 million from one of its supporters. This is the largest one-off donation the charity has ever received, and comes alongside an additional gift of £10 million from the same donor for the University of Southampton. [Cancer Research UK ] Press Release

POLICY NEWS

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

EVENTS

NEW 6th Australian Health and Medical Research Congress
November 25-28, 2012
Adelaide, Australia

Visit our events page to see a complete list of events in the prostate cell community.